任子行 reported revenue of ¥0.13B for the period ended 2026-06-30, +16.4% year on year. Net income was ¥-0.05B, a -38.7% net margin on a 63.3% gross margin. The largest revenue line is 网资管理 at 54% of the total. Free cash flow for the period was ¥-0.02B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.13B | +16.4% |
| Gross profit | ¥0.08B | — |
| Operating income | ¥-0.03B | — |
| Net income | ¥-0.05B | — |
| Gross margin | 63.3% | Net margin -38.7% |
| Revenue Q/Q | +48.9% | — |
| Segment | Revenue | Share |
|---|---|---|
| 网资管理 | ¥0.07B | 53.9% |
| 网络安全 | ¥0.06B | 44.7% |
| 其他(补充) | ¥0.00B | 1.4% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.05B | 36.7% |
| R&D | ¥0.06B | 47.6% |
| SG&A | ¥0.07B | 51.8% |
| Tax & other | ¥0.02B | 11.7% |
| Item | Amount |
|---|---|
| Total assets | ¥1.22B |
| Total liabilities | ¥0.56B |
| Shareholders' equity | ¥0.67B |
| Equity / assets | 54.6% |
| Operating cash flow | ¥-0.02B |
| Capital expenditure | ¥0.00B |
| Free cash flow | ¥-0.02B |
| Cash conversion (OCF / net income) | 144% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
天山生物 ・ 戴维医疗 ・ 掌趣科技 ・ 珈伟新能 ・ 博晖创新 ・ 麦捷科技 ・ 海达股份 ・ 同大股份 ・ 硕贝德 ・ 华灿光电 ・ 旋极信息 ・ ST凯利
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies